Veracyte
Veracyte Inc is an American genomic diagnostics company providing novel diagnostic tests for cancer and thyroid disorders. The company develops and commercializes genomic tests including Afirma, Decipher, Percepta, and Envisia, utilizing machine learning and RNA sequencing. Revenue is generated from diagnostic testing services provided through its CLIA-certified laboratory alongside diagnostic product kit sales to pathology centers. Core end markets serve endocrinologists, urologists, pulmonologists, oncologists, and clinical health networks in the United States and international markets. Veracyte occupies a leading position in genomic cancer diagnostics, guiding treatment decisions in early-stage cancer management. The company is headquartered in South San Francisco, California, and its common stock trades on the Nasdaq Global Select Market.
7 of the funds FundTelligence covers report a position in Veracyte.
- Legal name
- Veracyte Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 7
- Exposure themes
- Cancer Profiling, Molecular Diagnostics, Precision Medicine & Genomics
Funds holding Veracyte
- Nordea BetaPlus Enhanced Global Sustainable Small Cap — Nordea Funds · 0.34 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.19 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.12 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.06 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.05 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.05 % (partially disclosed portfolio, June 2026)
- Nordea Internationale aktier — Nordea Funds · 0.02 % (full portfolio disclosed, September 2026)